Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cost of Revenue for 8 consecutive years, with $17.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 89.25% year-over-year to $17.6 million, compared with a TTM value of $52.1 million through Dec 2025, up 53.24%, and an annual FY2025 reading of $52.1 million, up 53.24% over the prior year.
  • Cost of Revenue was $17.6 million for Q4 2025 at Neurocrine Biosciences, up from $14.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $17.6 million in Q4 2025 and bottomed at $2.9 million in Q1 2021.
  • Average Cost of Revenue over 4 years is $8.7 million, with a median of $8.5 million recorded in 2023.
  • The sharpest move saw Cost of Revenue dropped 11.76% in 2024, then surged 89.25% in 2025.
  • Year by year, Cost of Revenue stood at $4.2 million in 2021, then skyrocketed by 102.38% to $8.5 million in 2023, then increased by 9.41% to $9.3 million in 2024, then soared by 89.25% to $17.6 million in 2025.
  • Business Quant data shows Cost of Revenue for NBIX at $17.6 million in Q4 2025, $14.0 million in Q3 2025, and $11.3 million in Q2 2025.